Federal Circuit Wades Into Article III Standing in Patent Cases Once Again

Federal Circuit Wades Into Article Iii Standing In Patent Cases Once Again

Federal Circuit Wades Into Article III Standing in Patent Cases Once Again

By: Ashley E. Sperbeck and Mark D. McBriar Ph.D.

Article III standing can differ from the statutory requirements of 35 U.S.C. § 281 in patent cases. In certain instances, a secured creditor can obtain rights that become actionable only upon default, which may include the ability to license or enforce a patent. However, these rights may not necessarily correspond to patent ownership. Because Article III standing must exist when a case is filed, parties planning to file a complaint should consider the issue carefully beforehand. The precedential decision of Intellectual Tech LLC v. Zebra Techs. Corp.[1] illustrates this scenario.

OnAsset granted a security interest in U.S. Patent No. 7,233,247 to Main Street Capital Corporation (“Main Street”) as part of a loan agreement.[2] Several years later, OnAsset formed Intellectual Tech LLC (“IT”) as its subsidiary and assigned the same patent to IT,[3] which then granted a security interest in the patent to Main Street.[4] Subsequently, OnAsset and IT each defaulted on their respective agreements,[5]which afforded Main Street the option to sell, assign, transfer, and/or enforce the patent.[6]

 IT later sued Zebra Technologies (“Zebra”) for infringing the patent.[7] The district court granted Zebra’s motion to dismiss for lack of Article III standing, determining that Main Street’s right to license deprived IT of all its exclusionary rights, even if those rights were not exercised.[8]

On appeal, the Federal Circuit emphasized that Article III standing is a jurisdictional requirement not curable by joinder and, in contrast,[9] whether a party qualifies as a “patentee”[10] under 35 U.S.C. § 281 is not a jurisdictional requirement[11] and is curable by joinder.[12] In reversing the lower court’s ruling, the Federal Circuit found that (1) the triggering of Main Street’s unexercised option to assign[13] and (2) the shared ability to license while a default existed did not divest IT of all[14] The Federal Circuit concluded that, because Main Street did not exercise any options under the agreements, IT was not presently divested of all exclusionary rights.[15]

*****

[1] Intellectual Tech LLC v. Zebra Techs. Corp., No. 2022-2207 (Fed. Cir. May 1, 2024).

[2] See Intellectual Tech LLC, 2022-2207, slip op. at 3.

[3] See id.

[4] See id.

[5] See Intellectual Tech LLC, 2022 WL 1608014, at *3–4.

[6] See id., at *3. See also Sections 3(j), 6(b), and 6(c) of the Agreements.

[7] See Intellectual Tech LLC, 2022 WL 1608014, at *1.

[8] See id., at *7.

[9] See Intellectual Tech LLC, 2022-2207, slip op. at 9.

[10] See id. See also 35 U.S.C. § 100(d).

[11] See Intellectual Tech LLC, 2022-2207, slip op. at 10.

[12] See id., at slip op. at 11.

[13] See id., at slip op. at 11–12.

[14] See id., slip op. at 14.

[15] See id., slip op. at 16.

Ashley E. Sperbeck
Associate

Ashley Sperbeck focuses her practice on domestic and international patent prosecution, as well as IP due diligence, counseling, and portfolio management. She has extensive experience in several technical areas, including small molecule pharmaceuticals, medical devices, and life sciences.

More

Mark D. McBriar Ph.D.
Of Counsel

Mark D. McBriar focuses his practice on patent drafting and prosecution, IP due diligence, freedom to operate, patentability evaluations, re-examinations, and litigation support. Dr. McBriar works with pharmaceutical and life sciences companies on small molecule pharmaceutical compounds, synthetic methods, drug discovery, and methods of treatment. Dr. McBriar drafts and prosecutes U.S. patent applications and directs foreign patent prosecution relating to various pharmaceutical and biotechnology matters.

More

TopicsAgtechAI + RoboticsAnnouncementsAntitrustAsiaBioinformaticsBiotechBlockchainCell + Gene TherapyCFIUSCorporate + Venture CapitalCOVID-19Data AnalyticsDigital HealthEmploymentEuropean UnionFDAFinancingGlobalHealthcareIntellectual PropertyLicensing + CommercialLitigationMedical Devices + DiagnosticsPharmaPrivacy + Data SecurityProduct Liability + Class ActionRare DiseaseRegulatoryStartupUnited KingdomUnited States

Recent Posts